EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management

Natasha Szuber iD, Attilio Orazi iD, Ayalew Tefferi iD

American Journal of Hematology · 2024-07 · 99 (7) · 1360-1387

DOI: 10.1002/ajh.27321 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 21.04.2024. Verfasst von Natasha Szuber und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic neutrophilic leukemia (CNL) is a rare BCR :: ABL1 ‐negative myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis and bone marrow granulocyte hyperplasia. Atypical chronic myeloid leukemia (aCML) (myelodysplastic “[ MDS ]/ MPN with neutrophilia ” per World Health Organization [WHO]) is a MDS/MPN overlap disorder featuring dysplastic neutrophilia and circulating myeloid precursors. Both manifest with frequent hepatosplenomegaly and less commonly, bleeding, with high rates of leukemic transformation and death. The 2022 revised WHO classification conserved CNL diagnostic criteria of leukocytosis ≥25 × 10 9 /L, neutrophils ≥80% with 67 years, hemoglobin

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Neutrophilic, ChronicLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeHumansMutationRisk AssessmentReceptors, Colony-Stimulating FactorCarrier ProteinsNuclear Proteins

Substanzen

CSF3R protein, humanReceptors, Colony-Stimulating FactorSETBP1 protein, humanCarrier ProteinsNuclear Proteins

Autor:innen und Institutionen

  • Department of Hematology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
  • Department of Pathology, Texas Tech University Health Sciences Center, El Paso, Texas, USA.
  • Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Natasha Szuber, Attilio Orazi, Ayalew Tefferi

Zitieren

APA

Szuber, N., Orazi, A., & Tefferi, A. (2024). Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management. American Journal of Hematology, 99(7), 1360-1387. https://doi.org/10.1002/ajh.27321

Vancouver

Szuber N, Orazi A, Tefferi A. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management. American Journal of Hematology. 2024;99(7):1360-1387. doi:10.1002/ajh.27321

BibTeX
@article{Szuber2024,
  author = {Szuber, Natasha and Orazi, Attilio and Tefferi, Ayalew},
  title = {Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {7},
  pages = {1360--1387},
  doi = {10.1002/ajh.27321}
}
Kostenlos starten →